Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.45 |
| ▸ | CCR3 | P51677 | 4/20 | 0.43 |
| ▸ | HRH1 | P35367 | 3/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2212807 | 0.88 | UTS2R (0.42) | UTS2RCCR3HRH1MCHR1DRD2 | |
| SCHEMBL2214718 | 0.87 | UTS2R (0.48) | UTS2RCCR3MCHR1DRD2DRD4 | |
| SCHEMBL2210537 | 0.85 | UTS2R (0.46) | UTS2RCCR3HRH1MCHR1DRD2 | |
| SCHEMBL2214918 | 0.80 | MEN1 (0.42) | UTS2RCCR3HRH1MCHR1DRD2 | |
| SCHEMBL12510967 | 0.76 | UTS2R (0.46) | UTS2RCCR3MCHR1MEN1KMT2A | |
| SCHEMBL2213989 | 0.76 | UTS2R (0.46) | UTS2RCCR3HRH1MCHR1DRD2 | |
| SCHEMBL2211769 | 0.75 | UTS2R (0.44) | UTS2RCCR3HRH1MCHR1DRD2 | |
| SCHEMBL2213246 | 0.75 | UTS2R (0.63) | UTS2RCCR3HRH1MCHR1MEN1 | |
| SCHEMBL18841170 | 0.74 | HRH1 (0.70) | UTS2RCCR3HRH1MCHR1MAOB | |
| Trifluoroacetic Acid SCHEMBL2210369 | 0.72 | UTS2R (0.47) | UTS2RCCR3HRH1MCHR1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1389616-B1 | 3,4-Dihalobenzylpiperidine derivatives and their medical use | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-7115635-B2 | Benzylpiperidine compound | MITSUBISHI PHARMA CORPORATION (JP) | 2006-10-03 | — | — | US | disclosed |
| US-20040158071-A1 | Chemokine inhibitors and stability in blood | MITSUBISHI PHARMA CORPORATION (JP) | 2004-08-12 | — | — | US | disclosed |
| EP-1389616-A1 | NOVEL BENZYLPIPERIDINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2004-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040158071-A1 | Chemokine inhibitors and stability in blood | CCL2, CXCR1, CCR5 | UTS2R 2154/4885CCR3 21/4885HRH1 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.